| Entries |
| Document | Title | Date |
|---|
| 20130029943 | Methods of Preparing Substituted Tetracyclines with Transition Metal-Based Chemistries - The present invention relates to novel chemistries which allow for heretofore unobtainable substituted tetracycline compounds which exhibit significant activity in tetracycline responsive states. The methods disclosed herein utilize reactive tetracycline-based precursor compounds, reactive organic substituent precursors and transition metal catalysts under conditions such that a tetracycline compound substituted with the desired organic substituent is formed. In one embodiment of the invention, a substituted tetracycline compound may be prepared by combining a reactive tetracycline-based precursor compound such as an arene tetracycline diazonium salt, and a reactive organic substituent precursor, e.g., alkenes, substituted alkenes, vinyl monomers, aromatics and heteroaromatics, in the presence of a transition metal catalyst, such as palladium chloride, under conditions such that a tetracycline compound substituted with the organic substituent is formed. Such compounds may optionally act as intermediates for making other compounds, e.g., hydrogenation of unsaturated groups on the substituent. | 01-31-2013 |
| 20100022483 | Substituted Tetracycline Compounds - The present invention pertains, at least in part, to methods of treating a microorganism-associated infection in a subject comprising administering to said subject an effective amount of a tetracycline compound. | 01-28-2010 |
| 20100160263 | 7,9-SUBSTITUTED TETRACYCLINE COMPOUNDS - The present invention pertains to novel 7,9-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression. | 06-24-2010 |
| 20100113400 | 9-Aminomethyl Substituted Minocycline Compounds - The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and minocycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression. | 05-06-2010 |
| 20100075929 | 9-AMINOACYL TETRACYCLINE COMPOUNDS AND METHODS OF USE THEREOF - A compound of formula (I): | 03-25-2010 |
| 20100137261 | Method for treating aortic stenosis with non-antibacterial tetracycline formulations - The present invention is for a method for treating aortic stenosis in a mammal in need thereof. The method comprises administering an effective amount of a non-antibacterial tetracycline formulation, to the mammal. | 06-03-2010 |
| 20090306022 | 7-SUBSTITUTED TETRACYCLINE COMPOUNDS - The present invention pertains, at least in part, to novel 7-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression. | 12-10-2009 |
| 20120190652 | DIAGNOSTIC AGENT FOR PARKINSON'S DISEASE - The present invention relates to method of identifying whether or not an individual has Parkinson's disease (PD). In particular, the invention relates to a method for identifying whether or not an individual has PD in the pre-symptomatic phase of the disease or to distinguishing PD from another neurological disorder. The method of the invention comprises measuring the amount of soluble α-synuclein oligomers in a cerebrospinal fluid sample taken from an individual. The method optionally also comprises measuring the total amount of α-synuclein in the CSF sample, calculating the ratio of the amount of α-synuclein oligomers to the total amount of α-synuclein, and thereby determining whether or not the individual has PD. The method of the invention can be used in clinical trials to measure the effect of drugs in both PD animal models and human PD patients. | 07-26-2012 |
| 20110281827 | COMPOSITIONS, GELS AND FOAMS WITH RHEOLOGY MODULATORS AND USES THEREOF - The present disclosure relates generally to compositions for cosmetic or pharmaceutical application. The compositions include a carrier and rheology modulators. | 11-17-2011 |
| 20110294759 | Once daily formulations of tetracyclines - Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis. | 12-01-2011 |
| 20100035847 | GENES FOR BIOSYNTHESIS OF TETRACYCLINE COMPOUNDS AND USES THEREOF - The invention relates to genetically engineered cells, and to proteins and genes useful in the production of tetracycline compounds, to methods of producing tetracycline compounds, and to tetracyclines thereby produced. The present invention is based on the cloning and heterologous expression of genes encoding the chelocardin biosynthetic pathway. | 02-11-2010 |
| 20100035845 | TIGECYCLINE FORMULATIONS - The invention is directed to a frozen pharmaceutical formulation suitable for administration to a subject parenterally, comprising a therapeutically effective amount of tigecycline and an agent selected from the group consisting of lactose, dextrose, glucose, mannose, sucrose, ribose, xylose and a combination thereof, wherein the formulation in a pre-frozen state at about 22° C. or in an unfrozen state at about 22° C. has a pH in the range of from 4.0 to 5.5. Preferably, the formulation is suitable for storage at or below about −20° C. over a period of at least about 2 months, preferably 6 months, more preferably 26 months. Alternatively, the formulation is suitable for storage at about 22° C. over a period of about 24 hours. | 02-11-2010 |
| 20100035846 | METHOD FOR THE TREATMENT OF ACNE AND CERTAIN DOSAGE FORMS THEREOF - An oral dosage form, including 65 mg of minocycline, an amount of lactose monohydrate, and an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is hydroxypropylmethylcellulose that is about 8.9±0.2% hydroxypropoxylated. An oral dosage form, including 115 mg of minocycline, an amount of lactose monohydrate, and an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is hydroxypropylmethylcellulose that is about 8.9±0.2% hydroxypropoxylated. | 02-11-2010 |
| 20080312194 | Methods and compositions for normalizing meibomian gland secretions - The present invention provides non-aqueous compositions for normalizing meibomian gland secretions, and methods of use thereof. The present invention further provides compositions and methods for treating and/or preventing the signs and/or symptoms of dry eye disease. | 12-18-2008 |
| 20100113401 | METHODS FOR SYNTHESIZING AND PURIFYING AMINOALKYL TETRACYCLINE COMPOUNDS - Methods for the synthesis and purification of 9-amino alkyl tetracycline compounds are described. | 05-06-2010 |
| 20100113399 | Salts and Polymorphs of a Tetracycline Compound - Crystalline forms, including salts and polymorphs, of a compound useful in the treatment of tetracycline compound-responsive states are provided herein. The crystalline compounds are useful for the treatment or prevention of conditions and disorders such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds in general. | 05-06-2010 |
| 20090124583 | 7-N-substituted phenyl tetracycline compounds - 7-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted tetracycline compounds are described. | 05-14-2009 |
| 20090291925 | Bioactive polymeric liquid formulations of absorbable, segmented aliphatic polyurethane compositions - Bioactive liquid formulations are formed of combinations of absorbable, segmented aliphatic polyurethane compositions and liquid polyether for use as vehicles for the controlled release of at least one active agent for the conventional and unconventional treatment of different forms of cancer and the management of at least one type of bacterial, fungal, and viral infection. | 11-26-2009 |
| 20100249076 | PRODRUGS OF 9-AMINOMETHYL TETRACYCLINE COMPOUNDS - The invention pertains to prodrugs of 9-aminomethyl substituted tetracycline compounds, methods of using the compounds, and pharmaceutical compositions containing them. | 09-30-2010 |
| 20080207569 | Methods for the treatment of liver diseases - Provided herein are methods for treatment of a liver disease by administering a matrix metalloproteinase inhibitor. Also provided are methods for reducing liver damage associated with a liver disease by administering the matrix metalloproteinase inhibitor described herein. Further provided are methods for lowering an elevated level of liver enzymes by administering the matrix metalloproteinase inhibitor. | 08-28-2008 |
| 20090281068 | POLYLACTIDE COMPOSITIONS AND USES THEREOF - The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required. | 11-12-2009 |
| 20110207706 | Methods for Treating Spinal Muscular Atrophy Using Tetracycline Compounds - Methods for using tetracycline compounds for the treatment of spinal muscular atrophy are described. | 08-25-2011 |
| 20080287401 | Methods for Synthesizing and Purifying Aminoalkyl Tetracycline Compounds - Methods for the synthesis and purification of 9-amino alkyl tetracycline compounds are described. | 11-20-2008 |
| 20080306032 | 7-Phenyl-Substituted Tetracycline Compounds - 7-phenyl-substituted tetracycline compounds which are substantially free of positional isomers, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-phenyl-substituted tetracycline compounds are described. 7-substituted tetracycline compounds which are substantially free of positional isomers, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted tetracycline compounds are described. | 12-11-2008 |
| 20080312193 | Substituted Tetracycline Compounds for Treatment of Inflammatory Skin Disorders - Methods and compositions for the treatment of skin disorders (e.g., acne, rosacea) are described. | 12-18-2008 |
| 20080269175 | INCREASED DRUG LOADING CAPACITY OF POLYMERIC MATERIAL - A method includes (i) contacting a polymeric material with a first solvent to produce a pre-extracted polymeric material, and (ii) contacting the pre-extracted material with a solution comprising one or more therapeutic agents and a second solvent to incorporate the therapeutic agents into the pre-extracted polymeric material. The first or second solvents are the same or different. | 10-30-2008 |
| 20110207705 | OVIEDOMYCIN DERIVATIVES, METHOD FOR OBTAINING SAME AND USE THEREOF - Oviedomycin derivatives, method for obtaining same and use thereof. This invention relates to oviedomycin derivatives obtained by fermentation of recombinant bacterial strains. The invention also relates to the methods used to obtain the recombinant strains and to produce the oviedomycin derivatives. The invention further relates to bacterial strains that can be used to produce oviedomycin derivatives. Finally, said oviedomycin derivatives are applicable in the field of the human health, specifically to produce drugs for the treatment of tumour diseases. | 08-25-2011 |
| 20100004211 | 7-N-Substituted Phenyl Tetracycline Compounds - 7-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted tetracycline compounds are described. | 01-07-2010 |
| 20090325908 | 9-SUBSTITUTED MINOCYCLINE COMPOUNDS - The present invention pertains, at least in part, to novel 9-substituted minocycline compounds. These minocycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression. | 12-31-2009 |
| 20090054379 | 7-Pyrollyl 9-Aminoacyl Tetracycline Compounds and Methods of Use Thereof - A compound of formula (I): | 02-26-2009 |
| 20090253660 | Minocycline Compounds and Methods of Use Thereof - Methods and compositions for using a tetracycline compound to treat bacterial infections are described. In one embodiment, for example, the invention provides a method of treating a subject for an infection, comprising administering to said subject an effective amount of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, such that said subject is treated, wherein said infection is selected from the group consisting of MSSA, MRSA, B-streptococci, Viridans Streptococci, | 10-08-2009 |
| 20100152142 | CRYSTALLINE FORM II OF TIGECYCLINE AND PROCESSES FOR PREPARATION THEREOF - The present invention provides processes for the preparation of crystalline forms of Tigecycline. | 06-17-2010 |
| 20100190756 | 3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS - The present invention pertains to novel 3, 10, and/or 12a-substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression. | 07-29-2010 |
| 20110118215 | 7,8 And 9-Substituted Tetracycline Compounds - 7, 8 and 9-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7, 8 and 9-substituted tetracycline compounds are described. | 05-19-2011 |
| 20110009371 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF - The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetracycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-proliferative agents in the treatment of diseases of humans or other animals. | 01-13-2011 |
| 20100160265 | 7, 8 AND 9-SUBSTITUTED TETRACYCLINE COMPOUNDS - 7, 8 and 9-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7, 8 and 9-substituted tetracycline compounds are described. | 06-24-2010 |
| 20110034422 | DENDRIMERS FOR SUSTAINED RELEASE OF COMPOUNDS - Dendrimer-based compositions and methods are provided, that are useful for administering pharmaceutical compositions to target cells and tissues for treatment of ocular diseases including macular degeneration, diabetic retinopathy, and retinitis pigmentosa. | 02-10-2011 |
| 20110086821 | Tetracycline Compounds for Treatment of Cryptosporidium Parvum Related Disorders - Methods and compositions for treating | 04-14-2011 |
| 20090069274 | INTERFERON-LIKE PROTEIN ZCYTO21 - The present invention relates to polynucleotide and polypeptide molecules for Zcyto21, an interferon-like protein, which is most closely related to interferon-α at the amino acid sequence level. The present invention also includes antibodies to the Zcyto21 polypeptides, and methods of using the polynucleotides and polypeptides. | 03-12-2009 |
| 20110086822 | Substituted Tetracycline Compounds - The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for minocycline and tetracycline compounds in general, such as blocking tetracycline efflux and modulation of gene expression. | 04-14-2011 |
| 20120245130 | Methods of Using Substituted Tetracycline Compounds to Modulate RNA - A method for modulating RNA with tetracycline compounds is described. | 09-27-2012 |
| 20090258842 | 7-Phenyl-Substituted Tetracycline Compounds - 7-phenyl-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-phenyl-substituted tetracycline compounds are described. | 10-15-2009 |
| 20110077225 | 4-Substituted Tetracyclines and Methods of Use Thereof - The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds such as blocking tetracycline efflux and modulation of gene expression. | 03-31-2011 |
| 20110039805 | METHOD FOR TREATING MEIBOMIAN GLAND DISEASE - A method for treating a patient having meibomian gland disease, ocular irritation associated with delayed tear clearance, or recurrent corneal epithelial erosion, is disclosed. Preferably, the method concerns treatment of a patient with topical tetracycline, a derivative or analogue of tetracycline, or a chemically modified tetracycline (CMT). Oral administration of a CMT is also disclosed as part of the method for treating meibomian gland disease, ocular irritation associated with delayed tear clearance, or recurrent corneal epithelial erosion. | 02-17-2011 |
| 20080249072 | Use of Low Dose Chemically Modified Tetracylines to Reduce Inflammatory Mediators - The invention is a method for reducing the production of inflammatory mediators, and/or treating conditions characterized by increased levels of inflammatory mediators, in a mammal in need thereof, by administering a 4-dedimethlaminosancycline to the mammal. | 10-09-2008 |
| 20090118240 | LOCAL TREATMENT OF NEUROFIBROMAS - A method for treating a neurofibroma, e.g. dermal neurofibroma, a subdermal neurofibroma, or a superficial plexiform neurofibroma, in a subject in need of such treatment is disclosed. The method comprises locally applying a composition to a neurofibroma either topically or intralesionally. This method does not encompass systemic administration of the composition to the subject to have an effect on the neurofibromas. Compositions useful for such treatments and methods of preparing the compositions are disclosed. | 05-07-2009 |
| 20080242641 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 10-02-2008 |
| 20080242642 | MINOCYCLINE ORAL DOSAGE FORMS FOR THE TREATMENT OF ACNE - Minocycline oral dosage forms containing a controlled release carrier are useful for the treatment of acne. | 10-02-2008 |
| 20100190755 | TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS AND RELATED METHODS OF TREATMENT - The present invention pertains, at least in part, to substituted tetracycline compounds. The present invention also pertains to methods for treating rheumatoid arthritis in a subject, comprising administering to the subject a tetracycline compound of the invention. | 07-29-2010 |
| 20100160264 | CRYSTALLINE SOLID FORMS - The present invention relates to the new crystalline solid form VI and VIII of tigecycline and processes for the production of form VI and VIII. It further relates to a new method for preparing Form I and Form III in high polymorphic purity. | 06-24-2010 |
| 20080318910 | Controlled-Release Oral Dosage Form - A controlled-release oral dosage form suitable for administration to a mammal. The dosage form comprises a drug and an organic acid or a salt thereof. The dosage form releases no more than 60% the total amount of the drug within about a first hour, the remaining amount of the drug being released over a period of time of about 5 to about 8 hours subsequent to the first hour. Such a dosage form can be particularly useful for delivery of various pH-dependent solubility drugs. | 12-25-2008 |
| 20120208788 | Tetracycline Compounds - The present invention is directed to a compound represented by Structural Formula (1): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use. | 08-16-2012 |
| 20120046249 | METHODS OF REDUCING THE RISK OF CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN - The present invention features materials and methods for reducing the risk of cardiovascular disease in postmenopausal or perimenopausal women. More specifically, these methods can be used in women who generally have no apparent cardiovascular disease. We describe herein methods of administering non-antibacterial tetracycline or a sub-antimicrobial amount of antibacterial tetracyclines or tetracycline formulations and their use in reducing the risk that cardiovascular disease will develop in a subject (e.g., in a post- or perimenopausal woman) | 02-23-2012 |
| 20120115819 | Pentacycline Compounds - The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use. | 05-10-2012 |
| 20120115818 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO - Efficient method for preparing the enone intermediate (VII) used in the synthesis of tetracyclines derivatives. In particular, the invention provides a synthesis which allows for substituents at positions 4 | 05-10-2012 |
| 20120022026 | METHOD OF TREATING CANCER - The present invention relates to a method of treating or preventing hyperproliferative disease in a body tissue of a subject, comprising the steps of administering to a subject in need thereof a therapeutically effective amount of an agent that induces double strand breaks in the DNA of the hyperproliferative cells of said body tissue; and subjecting the hyperproliferative cells of said body tissue prior to, simultaneously with or subsequent to step a) to hyperthermia to thereby induce in said cells the degradation, inhibition and/or inactivation of BRCA2. | 01-26-2012 |
| 20120022025 | CRYSTALLINE FORM C OF TIGECYCLINE DIHYDROCHLORIDE AND METHODS FOR ITS PREPARATION - The present invention relates to crystalline form C of Tigecycline dihydrochloride and to methods for the preparation of the same. Furthermore the present invention relates to the use of crystalline form C of Tigecycline dihydrochloride as an intermediate for the preparation of an anti-infective medicament. Moreover the present invention relates to pharmaceutical compositions comprising crystalline form C of Tigecycline dihydrochloride in an effective amount and to the use of crystalline form C of Tigecycline dihydrochloride as an anti-infective medicament. | 01-26-2012 |
| 20100210602 | PhoU (PerF), A PERSISTENCE SWITCH INVOLVED IN PERSISTER FORMATION AND TOLERANCE TO MULTIPLE ANTIBIOTICS AND STRESSES AS A DRUG TARGET FOR PERSISTER BACTERIA - The PhoU protein is a widely expressed protein in bacteria, but not in eukaryotes. The PhoU protein is required for persister formation in bacteria. The invention includes compositions to reduce persister formation and their use as therapeutic agents. The invention further includes methods for identification of compounds to reduce persister formation. The invention further includes kits for the identification of agents that modulate the activity and expression of PhoU. | 08-19-2010 |
| 20120028928 | Process for Isolating Tigecycline and Tigecycline Made Therefrom - The present invention provides a process for isolating tigecycline which process comprises the step of spray drying a solution of tigecycline in a solvent. Preferably the solvent is water or an organic solvent. In another aspect, there is provided tigecycline obtainable by spray drying, particularly in amorphous form. In particular, the invention provides tigecycline obtainable by spray drying according to the process of the invention. | 02-02-2012 |
| 20120108552 | METHODS OF TREATING ACNE - A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound. | 05-03-2012 |
| 20120208789 | HYDROSWELLABLE, SEGMENTED, ALIPHATIC POLYURETHANES AND POLYURETHANE UREAS - Hydroswellable, absorbable and non-absorbable, aliphatic, segmented polyurethanes and polyurethane-urea capable of swelling in the biological environment with associated increase in volume of at least 3 percent have more than one type of segments, including those derived from polyethylene glycol and the molecular chains are structurally tailored to allow the use of corresponding formulations and medical devices as carriers for bioactive agents, rheological modifiers of cyanoacrylate-based tissue adhesives, as protective devices for repairing defective or diseased components of articulating joints and their cartilage, and scaffolds for cartilage tissue engineering. | 08-16-2012 |
| 20110092467 | 7-And 9-Carbamate, Urea, Thiourea, Thiocarbamate, And Heteroaryl-Amino Substituted Tetracycline Compounds - Substituted tetracycline compounds, methods of synthesis, and methods of use are discussed. Tetracyclines useful for treating tetracycline related disorders are also discussed. Intermediates useful for synthesizing other tetracycline compounds are also included. | 04-21-2011 |
| 20090137533 | Convenience Kit for Eyelid Treatment - The present invention offers an eyelid treatment kit used for convenient combination therapy for improving overall eyelid hygiene while also providing for adjunctive eyelid therapy. The eyelid treatment kit comprises low dose doxycycline hyclate tablets, a non-irritating eyelid cleansing composition, an anti-bacterial eyelid preparation and at least one pair of moist heat goggles and/or one pair of moisture chamber goggles. The eyelid treatment kit further comprises instruction sheets containing dosage and administration information on the doxycycline hyclate coupled with information on improving eyelid hygiene. The various embodiments of the eyelid treatment kit of the invention facilitate treatment of dry eyes due to infected eyelids, and proper cleansing of the eyelids to prevent recurring infections. | 05-28-2009 |
| 20120135968 | Tetracycline Compounds - The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use. | 05-31-2012 |
| 20080214510 | Methods and compositions for treating meibomian gland disease - A method for treating a patient having meibomian gland disease, ocular irritation associated with delayed tear clearance, or recurrent corneal epithelial erosion, is disclosed. Preferably, the method concerns treatment of a patient with topical tetracycline, a derivative or analogue of tetracycline, or a chemically modified tetracycline (CMT). Oral administration of a CMT is also disclosed as part of the method for treating meibomian gland disease, ocular irritation associated with delayed tear clearance, or recurrent corneal epithelial erosion. | 09-04-2008 |
| 20090111776 | Novel tetracycline derivatives as antibacterial agents - In accordance with one aspect, the present invention provides a compound of general formula (I), its stereoisomers thereof and/or its pharmaceutically acceptable salts thereof, which have antibacterial activity; with methods of treating infectious diseases in warm blooded animals employing these new compounds. | 04-30-2009 |
| 20100305072 | Substituted Tetracycline Compounds - The present invention pertains, at least in part, to novel substituted tetracycline compounds. These tetracycline compounds can be used to treat numerous tetracycline compound-responsive states, such as bacterial infections and neoplasms. | 12-02-2010 |
| 20100292193 | RADIOPROTECTIVE DRUGS - Drugs and their compositions useful in preventing and treating negative side effects associated with radiation exposure or clinical radiotherapy are disclosed. More specifically, new compounds that can be administered systemically to patients exposed to radiation or undergoing radiotherapy and methods of using these formulations are disclosed. | 11-18-2010 |
| 20120220555 | Methods of Simultaneously Treating Ocular Rosacea and Acne Rosacea - A method for simultaneously treating ocular rosacea and acne rosacea in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat ocular rosacea and acne rosacea but has substantially no antibiotic activity. | 08-30-2012 |
| 20100204186 | AROMATIC A-RING DERIVATIVES OF TETRACYCLINE COMPOUNDS - Aromatized A-ring derivatives of tetracycline compounds are described. | 08-12-2010 |
| 20120322770 | THERAPEUTIC COMPOUNDS FOR BLOCKING DNA SYNTHESIS OF POX VIRUSES - This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula I, formula XXI, formula XXXII, or formula XLI which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula I, formula XXI, formula XXXII, or formula XLI can be utilized to treat humans and animals suffering from a poxvirus infection. Pharmaceutical compositions for treating poxvirus infected subjects are also provided. | 12-20-2012 |
| 20110230452 | Compounds and methods for the treatment of pain and other diseases - The present invention relates generally to pharmaceutical agents, and in particular, to metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of dual acting MMP-2 and MMP-9 inhibiting compounds that exhibit increased potency, metabolic stability and/or reduced toxicity in relation to currently known MMP-2 and MMP-9 inhibitors for the treatment of pain and other diseases. Additionally, the present invention relates to methods for treating pain, addiction and/or withdrawal symptoms in a patient comprising administering to the patient a pain-reducing effective amount of a present compound. | 09-22-2011 |
| 20120277197 | TIGECYCLINE FORMULATIONS - The invention is directed to a frozen pharmaceutical formulation suitable for administration to a subject parenterally, comprising a therapeutically effective amount of tigecycline and an agent selected from the group consisting of lactose, dextrose, glucose, mannose, sucrose, ribose, xylose and a combination thereof, wherein the formulation in a pre-frozen state at about 22° C. or in an unfrozen state at about 22° C. has a pH in the range of from 4.0 to 5.5. Preferably, the formulation is suitable for storage at or below about −20° C. over a period of at least about 2 months, preferably 6 months, more preferably 26 months. Alternatively, the formulation is suitable for storage at about 22° C. over a period of about 24 hours. | 11-01-2012 |
| 20120088739 | METHOD FOR TREATING MEIBOMIAN GLAND DISEASE - A method for treating a patient having meibomian gland disease, ocular irritation associated with delayed tear clearance, or recurrent corneal epithelial erosion, is disclosed. Preferably, the method concerns treatment of a patient with topical tetracycline, a derivative or analogue of tetracycline, or a chemically modified tetracycline (CMT). Oral administration of a CMT is also disclosed as part of the method for treating meibomian gland disease, ocular irritation associated with delayed tear clearance, or recurrent corneal epithelial erosion. | 04-12-2012 |
| 20120329760 | RNASE 7 AS A MARKER FOR INFECTION - Methods of identifying a subject having a urinary tract infection using RNase 7 are described. The methods include providing a test sample of urine from the subject, determining the level of RNase 7 in the test sample, and then comparing the level of RNase 7 in the test sample to the level of RNase 7 in a control. A higher level of RNase 7 in the test sample indicates that the subject has an acute urinary tract infection, whereas a lower level of RNase 7 in the test sample indicates that the subject only has a chronic urinary tract infection. | 12-27-2012 |
| 20120329761 | USE OF TIGECYCLINE FOR TREATMENT OF CANCER - Cancer stem cells exhibit different metabolic profiles from other cancer cells, such that they do not readily respond to treatment using conventional chemotherapeutic agents. Studies disclosed herein now demonstrate that the glycylcycline antibiotic tigecycline (a tetracycline derivative) exhibits anti-cancer activity, including activity against cancer stem cells. This anti-neoplastic activity appears to be due to inhibition of mitochondrial protein synthesis in the cancer cells. In preferred embodiments, the cancer to be treated is a hematological cancer, such as leukemia, lymphoma or myeloma. | 12-27-2012 |
| 20110319368 | Once daily formulations of tetracyclines - Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis. | 12-29-2011 |
| 20120101070 | 11a, 12-Derivatives of Tetracycline Compounds - 11a,12-dehydrotetracycline compounds are described. | 04-26-2012 |
| 20130012481 | CRYSTALLINE FORMS OF TIGECYCLINE HYDROCHLORIDE - The present invention relates to crystalline forms A and B of Tigecycline hydrochloride and to methods for the preparation of the same. Furthermore the present invention relates to the use of crystalline forms A and B of Tigecycline hydrochloride as intermediates for the formulation of an anti-infective medicament. Moreover the present invention relates to pharmaceutical compositions comprising crystalline form A of Tigecycline hydrochloride in an effective amount and to the use of crystalline form A of Tigecycline hydrochloride as anti-infective medicament. | 01-10-2013 |
| 20130012480 | CRYSTALLINE SALTS OF (4S,4AS,5AR,12AS)-4-DIMETHYLAMINO-3,10,12,12A-TETRAHYDROXY-7-[(METHOXY(ME- THYL)AMINO)-METHYL]-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDRO-NAPHTHACENE-- 2-CARBOXYLIC ACID AMIDE AND METHODS OF USING THE SAME - A crystalline mono hydrochloride salt of (4S,4aS,5aR,12aS)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide is disclosed having improved stability. In addition, a crystalline mono mesylate salt and crystalline mono sulfate salt of (4S,4aS,5aR,12aS)-4-dimethylamino-3,10,12,12a-tetrahydroxy-7-[(methoxy(methyl)amino)-methyl]-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydro-naphthacene-2-carboxylic acid amide are also disclosed having improved stability. A pharmaceutical composition containing the crystalline salts and methods of treating inflammatory skin disorders and bacterial infections comprising administering the crystalline salts are also disclosed. | 01-10-2013 |
| 20100130451 | SYNTHESIS OF TETRACYCLINES AND ANALOGUES THEREOF - The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetra-cycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-pro liferative agents in the treatment of diseases of humans or other animals. | 05-27-2010 |
| 20110160165 | 7-Pyrazolyl Tetracycline Compounds and Methods of Use Thereof - The present invention provides compounds of Formula (I) and related methods and formulations: | 06-30-2011 |
